Based in Plymouth Meeting, Pennsylvania, Beijing Med-Pharm Corp. (NASDAQ: BGJP) operates through its subsidiaries to provide pharmaceutical marketing and distribution for U.S. and western pharmaceutical companies wishing to reach the People’s Republic of China. The company offers marketing and promotional services to hospitals and other healthcare providers, and distribution services for western medicines, traditional Chinese medicines, bio-chemical medicines and more.

Beijing Med-Pharm’s product profile includes Propess, a vaginal insert used to “ripen” the cervix to prepare for induced childbirth; Anpo (ritodrine hydrochloride), a muscle relaxant for pre-term labor management; Misopess, a vaginal insert for cervical ripening and the induction of labor; and Fentora buccal tablets for pain management for cancer patients.

The company recently entered into an agreement with Shanghai Novartis Trading Ltd. to sell overactive bladder treatment Enablex in China. Per the agreement, Beijing Med-Pharm is expected to approach China’s State Food and Drug Association for exclusive rights to sell and market the drug in China for 10 years. Already on the market in the U.S., Enablex is used to treat urinary incontinence, urgency and frequency to those afflicted with an overactive bladder.

The company is governed by Martyn Greenacre, chairman of the board since July 2004, who brings more than 10 years of pharmaceutical management experience to the table; David Gao, CEO, who has held various positions at Motorola, including vice president and director of the Integrated Electronic System Sector; and Fred Powell, CFO, who comes to Beijing Med-Pharm with nearly 24 years of experience in financial services.

Let us hear your thoughts: Beijing Med-Pharm Corp. Message Board